Aralez Pharmaceuticals Inc. (ARLZ) Director Arthur S. Kirsch Acquires 50,000 Shares of Stock

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Director Arthur S. Kirsch purchased 50,000 shares of the company’s stock in a transaction dated Friday, December 8th. The shares were acquired at an average cost of $1.47 per share, for a total transaction of $73,500.00. Following the transaction, the director now owns 271,609 shares of the company’s stock, valued at $399,265.23. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

Aralez Pharmaceuticals Inc. (ARLZ) traded up $0.05 during midday trading on Wednesday, hitting $1.48. The stock had a trading volume of 687,800 shares, compared to its average volume of 851,068. The company has a current ratio of 1.00, a quick ratio of 0.92 and a debt-to-equity ratio of 4.64. Aralez Pharmaceuticals Inc. has a 52 week low of $0.95 and a 52 week high of $5.05.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last released its quarterly earnings results on Thursday, November 9th. The company reported ($0.37) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.02. The company had revenue of $24.30 million for the quarter, compared to analyst estimates of $22.87 million. Aralez Pharmaceuticals had a negative return on equity of 118.13% and a negative net margin of 112.89%. Aralez Pharmaceuticals’s revenue was up 78.7% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.32) earnings per share. research analysts anticipate that Aralez Pharmaceuticals Inc. will post -1.54 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ballentine Partners LLC raised its position in shares of Aralez Pharmaceuticals by 166.7% during the third quarter. Ballentine Partners LLC now owns 80,000 shares of the company’s stock worth $183,000 after purchasing an additional 50,000 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Aralez Pharmaceuticals by 0.3% during the first quarter. Goldman Sachs Group Inc. now owns 121,494 shares of the company’s stock worth $260,000 after purchasing an additional 354 shares during the period. Isthmus Partners LLC raised its position in shares of Aralez Pharmaceuticals by 0.8% during the second quarter. Isthmus Partners LLC now owns 154,387 shares of the company’s stock worth $208,000 after purchasing an additional 1,285 shares during the period. Brown Advisory Securities LLC acquired a new stake in shares of Aralez Pharmaceuticals during the third quarter worth about $394,000. Finally, Intrinsic Edge Capital Management LLC acquired a new stake in shares of Aralez Pharmaceuticals during the second quarter worth about $270,000. 19.60% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://transcriptdaily.com/2017/12/13/aralez-pharmaceuticals-inc-arlz-director-arthur-s-kirsch-acquires-50000-shares-of-stock.html.

About Aralez Pharmaceuticals

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Insider Buying and Selling by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)

Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply